Literature DB >> 1512236

Hepatic microsomal bilirubin UDP-glucuronosyltransferase. The kinetics of bilirubin mono- and diglucuronide synthesis.

J M Crawford1, B J Ransil, J P Narciso, J L Gollan.   

Abstract

Hepatic biotransformation of bilirubin to the hydrophilic species bilirubin mono- (BMG) and diglucuronide (BDG) by microsomal bilirubin UDP-glucuronosyl-transferase (GT) is a prerequisite for its physiologic excretion into bile. The reaction mechanism of bilirubin-GT and the access of bilirubin and BMG (the intermediate substrate) to the active site of bilirubin-GT are undefined. Highly purified [14C]bilirubin and [3H] BMG were coincubated with rat liver microsomes, and the initial rates of radiolabeled bilirubin glucuronide synthesis were measured. Although these substrates differ markedly in their hydrophilicity, no significant differences were observed in [14C]- and [3H]BDG rates of formation from equimolar [14C]bilirubin and [3H] BMG, in the absence or presence of soluble binding proteins (albumin and hepatic cytosol). In further kinetic studies, [14C]bilirubin and [3H]BMG exhibited mutually competitive inhibition of [3H]- and [14C]BDG synthesis, respectively, and [3H]BMG also inhibited [14C]BMG formation. Finally, unlabeled BMG and BDG inhibited the glucuronidation of [14C]bilirubin, with all three pigments yielding virtual Michaelis-Menten dissociation constants in the 10-20 microM range. These findings indicate that: 1) bilirubin-GT follows Michaelis-Menten kinetics for both bilirubin and BMG glucuronidation over the range of substrate concentrations employed; 2) the findings are consistent with a single active site for the enzymatic synthesis of both BMG and BDG; 3) bilirubin, BMG, and BDG bind competitively to this active site with comparable affinities; and 4) access of both bilirubin and BMG substrates to the enzymatic active site is reduced by soluble binding proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512236

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2010-07-28       Impact factor: 3.922

2.  Comparative analysis of bilirubin glucuronidation activity in canine and human primary hepatocytes using a 3D culture system.

Authors:  Hisayoshi Omori; Junko Chikamoto; Takayuki Hirano; Kazuhiko Besshi; Naoaki Yoshimura; Maki Hirata; Takeshige Otoi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2022-08-01       Impact factor: 2.723

3.  Mechanism of indinavir-induced hyperbilirubinemia.

Authors:  S D Zucker; X Qin; S D Rouster; F Yu; R M Green; P Keshavan; J Feinberg; K E Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

4.  Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9.

Authors:  Lan Tang; Ye Li; Wei-Ying Chen; Shan Zeng; Ling-Na Dong; Xiao-Juan Peng; Wen Jiang; Ming Hu; Zhong-Qiu Liu
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

5.  Comparative Studies on Multi-Component Pharmacokinetics of Polygonum multiflorum Thunb Extract After Oral Administration in Different Rat Models.

Authors:  Ninghui Ma; Yong Zhang; Liyan Sun; Yuan Zhao; Yue Ding; Tong Zhang
Journal:  Front Pharmacol       Date:  2021-06-17       Impact factor: 5.810

6.  Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase.

Authors:  J Seppen; P J Bosma; B G Goldhoorn; C T Bakker; J R Chowdhury; N R Chowdhury; P L Jansen; R P Oude Elferink
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

7.  Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.

Authors:  Kimberly S Collins; Ingrid F Metzger; Brandon T Gufford; Jessica B Lu; Elizabeth B Medeiros; Victoria M Pratt; Todd C Skaar; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2019-12-30       Impact factor: 3.922

8.  Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.

Authors:  Ingrid F Metzger; Troy C Quigg; Noam Epstein; Abdulateef O Aregbe; Nancy Thong; John T Callaghan; David A Flockhart; Anne T Nguyen; Colleen K Stevens; Samir K Gupta; Zeruesenay Desta
Journal:  Curr Ther Res Clin Exp       Date:  2014-09-27

9.  Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.

Authors:  K Yang; C Battista; J L Woodhead; S H Stahl; J T Mettetal; P B Watkins; S Q Siler; B A Howell
Journal:  Clin Pharmacol Ther       Date:  2017-02-17       Impact factor: 6.875

Review 10.  Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease.

Authors:  David G Levitt; Michael D Levitt
Journal:  Clin Exp Gastroenterol       Date:  2014-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.